Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast®: w/e 21 May 2021

Pearce IP BioBlast®: w/e 21 May 2021

12 May 21 | Celltrion released its Q1 2020 financial results, reporting that YoY sales of Celltrion biosimilars increased by 23%.  Celltrion announced that it is planning to complete Ph III trials of biosimilar bevacizumab in the first half of 2021, and that...
Pearce IP BioBlast®: w/e 21 May 2021

Pearce IP BioBlast®: w/e 14 May 2021

11 May | US | Alvotech filed a federal lawsuit against AbbVie in the US District Court of the Eastern District of Virginia, seeking to clear patent barriers relating to its biosimilar adalimumab, AVT02.  Alvotech alleges that AbbVie has sought to protect its product...
Pearce IP BioBlast®: w/e 21 May 2021

Pearce IP BioBlast®: w/e 07 May 2021

01 May 21 | Samsung Bioepis announced a new study demonstrating the structural, physicochemical and biological similarity between its SB11 (proposed ranibizumab biosimilar) and Lucentis®.  The BLA and MA for SB11 are currently before the FDA and EMA respectively. 03...
Pearce IP BioBlast®: w/e 21 May 2021

Pearce IP BioBlast®: w/e 30 April 2021

23 April | Boehringer Ingelheim announced results from a Ph III switching study of Cyltezo® (biosimilar adalimumab) with Humira® produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity and safety. 23 April | Samsung Bioepis released...
Pearce IP BioBlast®: w/e 21 May 2021

Pearce IP BioBlast®: w/e 23 April 2021

15 April 21 | US | The Centre for Biosimilars reported a poster presented at AMCP 2021 shows a New York state Medicaid biosimilar preference initiative was successful in increasing biosimilar use in 2019. Biosimilar substitution is not permitted at the pharmacy level...